구분 |
보고서 (영문) |
제약/바이오/임 상시험 |
Takeda’s Eohilia to Compete Sanofi’s Dupixent in Eosinophilic Esophagitis Treatment |
eConsent: The Overlooked Patient-Centric Tool |
The Magrolimab Trial Halt Highlights the Uncertainties in Anti-CD47 Immunotherapy |
The Tiny Pills That May Send Shockwaves Across Immunology |
Cell and Gene Therapy Landscape in the US |
Another Setback for Minerva’s Schizophrenia Treatment Roluperidone |
APAC Led in Trials for 2023, with the Majority in Phase II |
Oncology Emerges as Dominant Therapy Area for CRISPR Technology |
Allecra’s EXBLIFEP Provides Valuable New Weapon to Tackle ESBL Mediated AMR |
AbbVie and Genmab’s Epkinly Joins BiTE Competition in Follicular Lymphoma |
질환별 |
Comorbidities Associated with ADHD Present an Opportunity for Pipeline Products to Capture the Market |
Female Sexual Dysfunction: Competitive Landscape |
Shifting the Paradigm – Novel Approaches to Amyotrophic Lateral Sclerosis Therapy |
Cell & Gene Therapies in Hemophilia A & B |
Shifting Patterns in Cervical Cancer Cases in Women in Their 30s and 40s |
컨퍼런스/심포 지엄/학회/기타 |
IO360: First Allogeneic Dual CAR T-Cell Therapy Shows Promise in B Cell Non-Hodgkin Lymphom |
Biotech Funding Optimism Rises as 44% Predict Recovery in 2024 |
Market Cap Upturn for Top 20 Biopharma Companies with Obesity Drug Successes in 2023 |
AD/PD 2024: The Role of Blood-Based Biomarkers in Alzheimer’s Disease
|
AD/PD 2024: Promising Data for Monitoring Speech Deficits in Early Parkinson’s |